limepolt.blogg.se

"Brandon's passion and success in developing businesses is exactly what we are looking to bring to PAI," says Kurt Orlofski, CEO of PAI.

Under Rockwell's tutelage, PAI will implement more advanced strategies and continue to revolutionize the space of unit dose medicine and liquid pharmaceuticals so they can meet the ever-growing number of healthcare facilities that PAI serves. "In joining PAI I see a great opportunity to further develop the business and to deliver value to the network of customers that we serve." "For businesses to stay at the forefront of their industry as PAI has done for decades, it takes constant evolution and a quick understanding of new tools, technologies and strategies," says Rockwell. In this role, he helped shape the strategic direction of the company through its acquisitions of Edict, Anchen, JHP and the integration between Qualitest and Par. Prior to that, he worked for Par Pharmaceutical where he led the Business Development and Licensing function.

Rockwell has led teams in business development and strategy, portfolio management, and project management for nearly 15 years, most recently as Senior Vice President of Business Development and Strategy for Endo, where he was responsible for the generic, hospital, and branded divisions.

In his new role, Rockwell will oversee PAI's growth strategy, further solidifying the company's position as the number one manufacturer of quality liquid pharmaceuticals in the US. (PAI) today announced the appointment of Brandon Rockwell as Chief Operating Officer, bringing 15 years of business development experience to the company. GREENVILLE, S.C., Ma/PRNewswire/ - Pharmaceutical Associates, Inc.